Table 2.
Univariate KaplanMeier Analyses Evaluating Median Cumulative 1-Year and 2-Year Rates of Graft Failure, Post-LT Death, and Retransplantation, Stratified by HCC, HCV, and Treatment Era.
| 1 year |
2 years |
||||||
|---|---|---|---|---|---|---|---|
| Median | 95% CI | Median | 95% CI | ||||
| Graft failure | Non-HCC | 14.6% | 14.3% | 14.9% | 19.1% | 18.8% | 19.4% |
| HCC | 11.7% | 11.2% | 12.2% | 18.0% | 17.4% | 18.6% | |
| Non-HCV | 13.8% | 13.6% | 14.1% | 18.1% | 17.8% | 18.4% | |
| HCV | 14.5% | 14.1% | 14.9% | 20.7% | 20.2% | 21.1% | |
| Pre-DAA | 15.4% | 15.1% | 15.7% | 20.4% | 20.1% | 20.7% | |
| Post-DAA |
10.4% |
10.1% |
10.8% |
14.3% |
13.8% |
14.8% |
|
| 1 year | 2 years | ||||||
| Median |
95% CI |
Median |
95% CI |
||||
| Post-LT Death | Non-HCC | 11.5% | 11.3% | 11.7% | 15.6% | 15.3% | 15.8% |
| HCC | 9.3% | 8.8% | 9.7% | 15.3% | 14.8% | 15.9% | |
| Non-HCV | 10.8% | 10.5% | 11.0% | 14.6% | 14.3% | 14.9% | |
| HCV | 11.7% | 11.3% | 12.1% | 17.5% | 17.0% | 18.0% | |
| Pre-DAA | 12.0% | 11.8% | 12.3% | 16.6% | 16.3% | 16.9% | |
| Post-DAA |
8.5% |
8.1% |
8.8% |
12.1% |
11.7% |
12.6% |
|
| 1 year | 2 years | ||||||
| Median |
95% CI |
Median |
95% CI |
||||
| Retransplantation | Non-HCC | 3.4% | 3.3% | 3.6% | 4.1% | 4.0% | 4.3% |
| HCC | 2.6% | 2.4% | 2.9% | 3.2% | 2.9% | 3.4% | |
| Non-HCV | 3.4% | 3.2% | 3.5% | 4.0% | 3.9% | 4.2% | |
| HCV | 3.1% | 2.9% | 3.3% | 3.8% | 3.6% | 4.0% | |
| Pre-DAA | 3.7% | 3.6% | 3.9% | 4.5% | 4.3% | 4.6% | |
| Post-DAA | 2.1% | 1.9% | 2.3% | 2.5% | 2.3% | 2.7% | |
DAA = direct-acting antiviral; HCV = hepatitis C virus; HCC = hepatocellular carcinoma; LT = liver transplantation; CI = confidence interval.